Clinical research of unresectable liver cancer by treatment of licartin combined with TACE

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-08000250

Enrollment

Unknown

Registered

2008-12-24

Start date

2008-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Group B:accept LpTACE/LpGsTACE involved in the treatment of chemotherapy drugs: (THP) 40mg, (HCPT) 10mg

Group A:accept Licartin + LpTACE/LpGsTACE involved in the treatment of chemotherapy drugs: (THP) 40mg, (HCPT) 10mg.

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. the participation is entirely voluntary, good compliance, sign the informed consent form in person; 2. diagnosed to be hepatocellular carcinoma by clinical method, imaging method and tumor markers; and the surgeons determine who can not undergo surgery; 3. Confirmed to recurrent after surgery by pathology; 4. KPS score of physical state >=60 points; 5. liver function is Child-Pugh A or B class.

Exclusion criteria

Exclusion criteria: 1) General situation is poor and liver function Child-Pugh is C class; 2) there is a serious heart, kidney and blood system diseases in patients; 3) poor compliance; 4) There is allergy history of biological agents or in a state of allergy; 5) pregnancy and breast-feeding women.

Design outcomes

Primary

Measure	Time frame
The overall survival rate;	—

Secondary

Measure	Time frame
tumor size; AFP change;	—

Countries

China

Contacts

Public ContactYangYeFa

gelarge@163.com+86 0 13386270636

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026